What question did this study set out to answer?

The study aims to compare the efficacy and tolerability of risperidone to placebo and haloperidol in managing aggressive behavioral symptoms in dementia patients.

September 1, 1999Neurology

A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia

View Full Paper

Ask AI

Bookmark

Authors

PDPeter Paul De DeynBrigham Young University KRKiran RabheruUniversity of Ottawa ARAnne Mette L. RasmussenSteno Diabetes Centers

Discussion

Member takes

Implication

Randomized trial compares risperidone and haloperidol for treating behavioral symptoms in dementia, indicating potential benefits of risperidone.

Key Points

The study aims to compare the efficacy and tolerability of risperidone to placebo and haloperidol in managing aggressive behavioral symptoms in dementia patients.
13-week double-blind trial with 344 patients randomly assigned to risperidone, haloperidol, or placebo.
Behavioral symptoms assessed using BEHAVE-AD, CMAI, and CGI scales.
Tolerability evaluated through various scales, including Extrapyramidal Symptom Rating Scale and Mini-Mental State Examination.
Risperidone showed a clinically significant improvement in BEHAVE-AD total score at week 12 compared to placebo.
Aggression scores were significantly reduced with risperidone compared to both placebo and haloperidol at endpoint and week 12.
Extrapyramidal symptoms with risperidone were not significantly different from placebo and were less than those observed with haloperidol.

Cite This Study

Deyn et al. (1999) studied this question.

synapsesocial.com/papers/6a0043ceb124fe581985d017 https://doi.org/10.1212/wnl.53.5.946

View Full Paper

Ask AI

Bookmark

September 1, 1999Neurology

A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia

View Full Paper

Ask AI

Bookmark

Authors

PDPeter Paul De DeynBrigham Young University KRKiran RabheruUniversity of Ottawa ARAnne Mette L. RasmussenSteno Diabetes Centers

Discussion

Member takes

Implication

Randomized trial compares risperidone and haloperidol for treating behavioral symptoms in dementia, indicating potential benefits of risperidone.

Key Points

The study aims to compare the efficacy and tolerability of risperidone to placebo and haloperidol in managing aggressive behavioral symptoms in dementia patients.
13-week double-blind trial with 344 patients randomly assigned to risperidone, haloperidol, or placebo.
Behavioral symptoms assessed using BEHAVE-AD, CMAI, and CGI scales.
Tolerability evaluated through various scales, including Extrapyramidal Symptom Rating Scale and Mini-Mental State Examination.
Risperidone showed a clinically significant improvement in BEHAVE-AD total score at week 12 compared to placebo.
Aggression scores were significantly reduced with risperidone compared to both placebo and haloperidol at endpoint and week 12.
Extrapyramidal symptoms with risperidone were not significantly different from placebo and were less than those observed with haloperidol.

Cite This Study

Deyn et al. (1999) studied this question.

synapsesocial.com/papers/6a0043ceb124fe581985d017 https://doi.org/10.1212/wnl.53.5.946

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark